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Abstract
Background: Weight gain accompanies smoking cessation, but dieting during quitting is controversial as hunger
may increase urges to smoke. This is a feasibility trial for the investigation of a very low calorie diet (VLCD),
individual modest energy restriction, and usual advice on hunger, ketosis, urges to smoke, abstinence and weight
gain in overweight smokers trying to quit.
Methods: This is a 3 armed, unblinded, randomized controlled trial in overweight (BMI > 25 kg/m
2), daily smokers
(CO > 10 ppm); with at least 30 participants in each group. Each group receives identical behavioural support and
NRT patches (25 mg(8 weeks),15 mg(2 weeks),10 mg(2 weeks)). The VLCD group receive a 429-559 kcal/day liquid
formula beginning 1 week before quitting and continuing for 4 weeks afterwards. The modest energy restricted
group (termed individual dietary and activity planning(IDAP)) engage in goal-setting and receive an energy
prescription based on individual basal metabolic rate(BMR) aiming for daily reduction of 600 kcal. The control
group receive usual dietary advice that accompanies smoking cessation i.e. avoiding feeling hungry but eating
healthy snacks. After this, the VLCD participants receive IDAP to provide support for changing eating habits in the
longer term; the IDAP group continues receiving this support. The control group receive IDAP 8 weeks after
quitting. This allows us to compare IDAP following a successful quit attempt with dieting concurrently during
quitting. It also aims to prevent attrition in the unblinded, control group by meeting their need for weight
management. Follow-up occurs at 6 and 12 months.
Outcome measures include participant acceptability, measured qualitatively by semi-structured interviewing and
quantitatively by recruitment and attrition rates. Feasibility of running the trial within primary care is measured by
interview and questionnaire of the treatment providers. Adherence to the VLCD is verified by the presence of urin-
ary ketones measured weekly. Daily urges to smoke, hunger and withdrawal are measured using the Mood and
Physical Symptoms Scale-Combined (MPSS-C) and a Hunger Craving Score (HCS). 24 hour, 7 day point prevalence
and 4-week prolonged abstinence (Russell Standard) is confirmed by CO < 10 ppm. Weight, waist and hip circum-
ference and percentage body fat are measured at each visit.
Trial Registration: Current controlled trials ISRCTN83865809
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Weight gain is a well known consequence of smoking
cessation [1,2]. It may deter smokers from attempting to
quit [3] and offsets some advantages of giving up smok-
ing. Smoking cessation-related weight gain partly
explains the finding that the incidence of type II dia-
betes is increased by 50-100% in the years after cessa-
tion [4,5] and there is a 30% increased risk of
hypertension [6] compared to continuing smoking. The
improvement in lung function of quitters decreased by
38% in men and 17% in women as a consequence of
weight gain [7].
An ideal intervention to prevent weight gain would
begin at the time of quitting, because weight gain is
most rapid initially, and then the rate of gain slows [8].
However, initial weight management is controversial.
The main reason quit attempts fail is due to quitters
succumbing to their cravings to smoke. Evidence sug-
gests that hunger increases urges to smoke (smokers
smoke more when hungry)[9,10] and people who gain
most weight are more likely to succeed in quitting
smoking[11]. These observations led to attempts to
reduce cigarette cravings by using glucose tablets, which
was shown to be effective[12]. This suggests that avoid-
ing hunger and feeding cigarette cravings with food may
enhance smoking abstinence. Therefore current smoking
cessation advice is to avoid hunger and not to diet dur-
ing a quit attempt, although healthy food choices are
often advocated. However the hypothesis that dieting
while quitting increases hunger and thereby increases
urges to smoke in the early phases of a quit attempt has
not been tested in free living conditions. DeMiST is
designed to test this hypothesis and also builds on the
results of a Cochrane review[13], which investigated
weight gain prevention during smoking cessation. The
reviewers reported that general dietary education to
reduce energy intake through eating a low fat, healthy
diet did not prevent weight gain compared to standard
smoking cessation behavioural support. Furthermore,
t h e r ew a sas t a t i s t i c a l l ys i g n ificant reduction in absti-
nence at 12 months (Table 1). An individually tailored
dietary plan to reduce energy intake; with regular moni-
toring and adaptation of individual goals, reduced
weight gain at 6 and 12 months; without a statistically
significant reduction in abstinence rates (Table 1).
Intermittent use of a very low calorie diet (VLCD) pro-
vided the greatest effect on preventing weight gain at
end of treatment, but the effect was no longer statisti-
cally significant at 12 months and was lower than the
individual plan. However use of the VLCD showed a
statistically significant increased abstinence rate to
almost double that of controls at end of treatment and
long-term follow up (Table 1).
T h ee f f e c to ft h eV L C Do ni mproving abstinence is
unexpected. One hypothesis is that the VLCD induced
ketosis, which actually suppressed hunger [14] and
therefore reduced urges to smoke. This hypothesis is
supported by data supplied by Danielsson (personal
communication), which showed a statistically significant
reduction of urges to smoke and a smaller increase in
appetite during the weeks on the VLCD diet. There was
a 50% reduction in urges to smoke after 1 week on the
VLCD diet compared to a 27% reduction after 1 week
in the control group (P < 0.0001). There was a 4-fold
increase in hunger in the control group after 1 week
compared to only a 50% increase in hunger in the
VLCD group (p < 0.0003).
However the intermittent use of the VLCD in this
study might have concealed the full potential a VLCD to
reduce nicotine withdrawal symptoms. Swinging in and
out of a ketotic state is likely to have its own bearing on
mood and hunger regardless of nicotine withdrawal.
This study has also been criticised for lacking generalisi-
bilty into a health service setting, for only recruiting
women and only recruiting those who had previously
failed in quit attempts because of weight concerns.
DeMiST includes daily cigarette smokers regardless of
gender or previous quit attempts. Its primary aim is to
investigate the feasibility of running dietary interven-
tions as part of the National Health Service (NHS) stop
smoking service. Its secondary aim is to investigate the
association of hunger and urges to smoke. It will further
test whether ketosis, induced by a VLCD, reduces urges
to smoke through hunger suppression.
The effect of 3 dietary strategies on hunger and cigar-
ette craving will be compared. One is the VLCD, the
second is an individual dietary and activity plan (IDAP)
which includes a modest energy restriction, using a low
fat diet which meets the energy requirements of an indi-
vidual’s BMR. The third is a control condition where
Table 1 Effects of dietary interventions on weight change and abstinence during smoking cessation
Intervention compared to standard smoking cessation Mean difference in weight change (Kg [95%CI]) Abstinence (RR [95%CI])
End of treatment At 12 months End of treatment At 12 months
General lifestyle and calorie reducing dietary advice -0.04 [-0.57, 0.50] -0.21 [-2.28, 1.86] 0.90 [0.76, 1.06] 0.66 [0.48, 0.90]
Individually tailored dietary and lifestyle advice -1.05 [-2.01, -0.09] -2.58 [-5.11, -0.05] 1.11 [0.84, 1.46] 0.79 [0.47, 1.33]
VLCD compared to general calorie reducing dietary advice -3.70 [-4.82, -2.58] -1.30 [-3.49, 0.89] 1.40 [1.07, 1.85] 1.73 [1.10, 2.73]
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emphasis of avoiding hunger, this is typical of the cur-
rent advice given in NHS stop smoking services.
We expect hunger to be greatest in the IDAP group
where a moderate energy restriction creates a negative
energy balance. Appetite is then increased in response
to the usual physiological and neurological mechanisms
that work to restore energy homeostasis [15]. In the
control condition we are expecting hunger to be alle-
viated by eating freely.
The associations of hunger and craving scores within
and between these groups will be investigated. These
scores are recorded daily. The VLCD will begin one week
before quit day to ensure participants are in ketosis
before they quit (verified by the presence of urine
ketones) and will continue, uninterrupted, for a further 4
weeks when nicotine withdrawal is at its peak. The IDAP
will also begin one week before quit day to ensure that
participants are in a state of hunger when they quit. The
control group will be advised to eat as usual. Therefore
at the time of quitting we expect to see the maximal dif-
ferences in hunger scores between the 3 groups.
The greatest criticism of VLCDs in current clinical
practice is that they may not establish long term healthy
eating habits, although a review by NICE reported that a
5% reduction in body weight is maintained over 2 years
in those following a VLCD plan [16]. Our aim is to use
the results of this trial to inform a study large enough
and of long enough duration to assess long term effects
on dietary change, weight, cardiovascular risk, lung
health and smoking abstinence. For this reason we have
designed DeMiST to be a small scale model of such a
trial. Therefore DeMiST extends beyond the initial quit-
ting phase into a second treatment stage where both the
VLCD and the control group receive individually tai-
lored dietary advice.
The reason for this in the VLCD group is to provide
them with conventional support to establish long term
healthy habits. The reason for this in the control group is
two-fold. Firstly, because the control is unblinded we hope
that by providing IDAP after quitting this group will not
feel ‘short changed’ and abandon their quit attempt pre-
maturely. Secondly we will be compare the long term
effects from IDAP, which restricts energy intake at the
time of quitting, with the ‘control’ group which restricts it
after they have already quit. There is evidence to suggest
that the latter may be more successful than the former,
although this hasn’t been tested with an adequately pow-
ered trial, [17] we plan to do so in our future trial.
Methods
Participants
Overweight (BMI > 25 Kg/m
2) smokers listed on the
databases of participating general practices are invited to
take part by a letter from their General Practitioner
(GP). All participants are from practices in Birmingham
East and North Primary Care Trust (PCT) and Worces-
tershire PCT, in the UK. (See additional file 1 for sub-
stantial amendment to recruitment strategy).
Interested participants telephone the trial office at The
University of Birmingham for further information; they
provide verbal consent to initial telephone screening for
eligibility. If considered eligible they are given an
appointment with a trial nurse for full screening where
they are invited to give informed consent for participa-
tion. The trial office sends the patient information sheet
out so that it is received at least 24 hours before their
first appointment. The clinics are run at local GP prac-
tices, daytime appointments are offered from 8.30 am
until 7 pm.
Inclusion Criteria
￿ Aged over 18 years
￿ Daily cigarette smoker with an exhaled CO of at
least 10 ppm at least 15 minutes after last smoking
￿ BMI of at least 25 kg/m
2
￿ Willing to be randomised to any of the three arms
and willing and able to comply with the intervention
and all study procedures
We are recruiting only those with a BMI greater than
or equal to 25 for the following reasons: 1) The rate of
weight loss on a VLCD is approximately 2 kg/week so
anyone entering the trial would need to be able to lose
10 kg. For example, a woman 1.64 m tall weighing 68 kg
with a BMI of 25.2 could potentially lose 10 kg and reach
a healthy BMI of 21.6 kg/m
2. VLCDs have been shown to
be as safe in those with a BMI > 25 kg/m
2 as in those
with a BMI > 30 kg/m
2 [18]. 2) Research shows that
those who are overweight or obese are likely to gain
more weight than healthy weight smokers and so they
are an appropriate target for weight gain prevention [19].
3) The smoking population has a lower mean BMI than
the non-smoking population so we could potentially
struggle to recruit only those with a BMI >30 kg/m
2.
Exclusion Criteria
￿ Any of the absolute or relative contraindications to
VLCD use. These include situations in which rapid
weight loss would be unsafe: pregnancy, breastfeeding,
myocardial infarction/unstable angina/acute coronary
syndrome in the past 6 months, cerebrovascular acci-
dent/transient ischaemic attack/stroke in the past 3
months, major surgery in the last 3 months, severe
cardiac arrhythmias, severe hepatic impairment,
severe renal impairment (i.e. GFR ≤ 29 mls/min),
active carcinoma, untreated gallstones, past history of
anorexia nervosa or bulimia nervosa, type 1 diabetes,
those aged over 70 years with a BMI < 30. A large
energy deficit alters metabolic rate and so anyone
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den weight loss may cause fainting or precipitate gout
i nt h o s ew h oa r es u s c e p t i b l es ot h o s ew i t hr e g u l a r
blackouts or fainting, and untreated gout are also
excluded. The VLCD formula is made from milk so
is unsuitable for anyone with a milk allergy or
intolerance.
￿ Uncontrolled hypertension and type 2 diabetes
treated with medication. Although these are not
contraindications to the VLCD they are excluded as
adjusting the medications in these conditions would
require specialist advice beyond the scope of the
research nurses in this trial (diet controlled type 2
diabetics may be included).
￿ Those on oral anticoagulants, digoxin, phenytoin
and lithium are excluded due to likelihood of
increased drug absorption if on a VLCD. Specialist
advice beyond the scope of our research nurses is
needed to reduce and monitor these medications.
￿ Those on diuretics for diuresis are excluded as a
VLCD can potentiate diuresis and increase the risk
of hypokalaemia. Those on low dose diuretics for
treatment of hypertension are not excluded as the
risk is of hypokalaemic complications on these are
low [20,21]. The effects of combining a VLCD with
low dose thiazides has not been well studied and
may be unpredictable therefore serum potassium
will be monitored weekly and the VLCD discontin-
ued if levels fall below 3.1 mmol/l. (Additional file 2
contains full list of excluded medications).
￿ Previous severe adverse reaction to nicotine
patches (that which precludes further use).
￿ Active phaeocromocytoma as this combined with
u s eo fN R Tm a yi n c r e a s et h er i s ko fh y p e r t e n s i o n
and tachycardia.
￿ Currently using smoking cessation medication i.e.
nicotine replacement therapy (NRT), Vareniciline or
Bupropion or medication (e.g. nortriptyline) that is
known to help smokers quit.
￿ Those taking weight loss medication e.g. orlistat,
sibutramine.
￿ Suspected abuse of alcohol or other drug as this
might confound our measure of cravings.
￿ Use of any smokeless tobacco
￿ Currently participating in other therapeutic clinical
trials.
Removal of Patients from Therapy
￿ If a contraindication to treatment becomes
apparent.
￿ An adverse event occurs that makes it inadvisable
to continue treatment.
￿ If serum potassium falls below 3.1 mmol/l in those
taking thiazides, the VLCD will be discontinued.
￿ The person ceases to continue to quit smoking and
wishes also to abandon the weight management pro-
gramme. If a person fails to stop smoking they may
continue with the dietary treatment intervention,
likewise if a person abandons the dietary treatment
they may continue with their quit attempt. Keeping
participants like this in the trial will help us to
explore the reasons why a treatment was abandoned.
We will find out whether abandonment of one treat-
ment ultimately leads to abandonment of both and
how these participants have decided to tackle their
smoking or weight.
Interventions
Treatment Stage 1
This is for 8 weeks from -3 to + 4 (Figure 1). Week 0 is
quit week, negatively numbered weeks are the weeks
before quit day and positively numbered weeks are the
weeks after quit week. Week -3 is baseline, three weeks
before quit week. Participants are seen and briefed at
baseline and a quit day is set for three weeks time. Diet-
ary interventions commence one week prior to quit
week (week -1). Participants are randomised into either
the VLCD, IDAP or Control (SBS) arm as described
below.
VLCD The VLCD formula Lipotrim is provided for the
study at cost price from Howard Foundation Research
Ltd. It is purchased by participating Primary Care Trusts
(PCTs) and provided free to participants. Participants
take 2-3 shakes each day and drink a minimum of 4
pints of water, but not in excess of 4 litres. Black tea
and black coffee may be drunk but no other food or
drink can be consumed as any additional carbohydrate
or citric acid may suppress ketone production. The
female formula totals 425 kcal and the male formula
totals 559 kcal, it contains all essential nutrients and
complies with the EU codex standard for VLCDs [16].
This diet is begun 1 week before quitting, by which time
t h ed i e t e rs h o u l db ei nk e t o s i s .T h e yc o n t i n u et h i sd i e t
during the first 4 weeks after quitting when nicotine
withdrawal symptoms are at their worst. The rationale
for this is that they will be comfortably in ketosis when
they quit and when in acute nicotine withdrawal.
Every effort is made to get the participant to adhere to
the VLCD by using behavioural change techniques as
defined by Abraham and Michie [22]. These include an
explanation of the role of ketones and the necessity for
strict adherence in order to remain in a ketotic state.
(Providing instruction and providing information on
consequences of action are behavioural change techni-
ques 2 and 8.) Ketosis is usually achieved by the third
or fourth day on the diet and so participants are advised
that they will feel better after this time. Encouragement
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(technique 22) is used e.g. ‘today was difficult but if I
keep going I will feel better in 2 days’, ‘if I can stick this
out, I can lose weight and stop smoking in time for my
birthday’. Support to identify and overcome barriers to
adherence (technique 5) is also given.
Individually Dietary and Activity Planning (IDAP)
This contains dietary, activity and behavioural elements.
Assessment of current behaviours and food choices is
made by using the Health Choice Index (HCI). This is a
multiple choice questionnaire which asks the participant
to score their food choices, weekly food frequency, eat-
ing behaviours and activity. From this, both the partici-
pant and the healthcare professional can identify areas
for improvement and goals are then agreed. Typically
three goals are given particular attention, one focussing
on food choice e.g. I will buy skimmed milk instead of
full fat milk; one on eating behaviour e.g. ‘Iw i l lp r e p a r e
a packed lunch the night before to take to work so that
I don’t miss lunch’. And one activity focussed goal e.g. ‘I
will park the car a block away from work and take a
brisk walk at lunchtime so that I fit in 3 ten minute
exercise breaks during my working day. Prompting spe-
cific goal setting is technique 10 in the behavioural
change taxonomy. These goals are reviewed regularly
and adjusted as necessary (behaviour change technique
11). Helping the participant to identify and overcome
barriers to achieving their goals, discussing time man-
agement to incorporate these changes into their daily
lives, helping them to plan relapse prevention strategies
and general encouragement all form part of this inter-
vention (behavioural techniques 5, 26, 23 and 6
respectively).
As well as identification of specific goals instruction is
given (technique 8) for following a moderate calorie
restricted diet plan tailored to the individual’se n e r g y
requirements. This provides a structure to help consoli-
date the goals identified and ensure that the participant
h a st h er i g h tt o o l st oa c h i e v eas u f f i c i e n te n e r g yd e f i c i t
for weight control.
T h ee n e r g yp r e s c r i p t i o nu s ed in previous studies to
prevent weight gain on smoking cessation has varied.
Pirie et al calculated daily energy requirement minus
150 to 300 kcal/day (which is considered to equate to
metabolic slowing upon nicotine withdrawal, amount
depends on number of cigarettes smoked [23]. Perkins
et al used a 500 kcal deficit tailored to individual
requirements [24]. Hall used a 500 kcal deficit tailored
to individual requirements should weight increase by
1 kg [11]. Danielsson used a 1600 kcal diet [25].
We have decided to advise an approximate energy def-
icit of 600 kcal. This is recommended by NICE for
Figure 1 Phases in DeMiST.
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counter the mean rate of post-cessation weight gain and
promote modest weight loss which is desirable for our
population with a BMI > 25 kg/m
2.D i e t e t i cc o n s e n s u s
considers a usual maximum energy prescription of 1800
kcal. Anecdotally advising above this appears to be inef-
fective at achieving weight loss, this may be due to a
people misunderstanding the volumes of food recom-
mended for larger portion sizes.
To calculate energy prescription in individuals we
have assumed all participants will have a physical activ-
ity level (PAL) of 1.4, which is consistent with a seden-
tary occupation and leisure activities. The PAL is the
factor by which BMR is multiplied to give an estimate
of total energy expenditure. For simplicity in clinical
practice we have written dietary plans that equate to
energy intakes of 1200 kcal, 1500 kcal or 1800 kcal. An
individual is allocated the closest energy prescription to
their BMR (as calculated by the Tanita body composi-
tion analyser). Calculating total energy requirement
from a PAL of 1.4 and BMRs of 1200 kcal, 1500 kcal
and 1800 kcal, shows energy requirement is an increase
of 500 kcal-700 kcal above BMR. This means we can
approximately achieve the 600 kcal deficit by using
BMR alone for the prescription of energy. The energy
level advised is translated into the appropriate number
of portions from each of the food groups: complex car-
bohydrates, fruit and vegetables, meat, fish and alterna-
tives, dairy foods, sugar and fatty foods. The proportion
of food coming from these food groups make up a
healthy diet with 15-30% of energy from fat, 10-15% of
energy from protein, 55-75% of energy from carbohy-
drate and 0-5% energy from alcohol. Therefore the diet
is low in fat and alcohol, two things that studies have
shown significantly increase in the diets of smokers
when they quit [26-28]. The dietary plan is a ‘pick and
choose’ format, where individuals choose from a list of
items within different food groups at each meal. The
food portions are defined in American cup sizes and
participants are given measuring cups to measure out
their portions.
Control (Step by Step (SBS)) The control group
receives healthy eating advice when they mention weight
concern. This is standard in smoking cessation interven-
tions. Advice is given not to ‘diet’ but instead to avoid
hunger by eating healthy, low fat foods. This is because
it is thought that hunger may lead to urges to smoke,
a n dm a ym a k er e l a p s em o r elikely. Tips for avoiding
hunger include:
￿ Regular meals, including breakfast (which is often
missed in smokers)
￿ Handy, healthy snacks e.g. fruit or chopped vegeta-
bles (carrot, celery sticks)
￿ Drink plenty of water, particularly before meals,
this helps fill the stomach and satisfy ‘oral cravings’.
There is evidence that glucose tablets satiate urges to
smoke within minutes, so these can be used[12]. Avoid-
ance of excess or total alcohol for the immediate post-
cessation period is advised. This is to avoid lapsing due
to disinhibition and the ‘cue’ which alcohol provides,
rather than to avoid calories. Participants are advised to
increase daily activity, e.g. including a 30 minute walk in
their day. Advice in the control group is given as general
instruction and general encouragement (behavioural
techniques 6 and 8) but individual goal setting and
energy prescription is not included.
Treatment Stage 2
T h i ss p a n sf r o mw e e k+ 4t o+ 1 2a n di n c l u d e s4v i s i t s
(Figure 1). The same number of visits has been included
in each of the intervention arms so that number of con-
sultations with a healthcare professional is not a
confounder.
VLCD The VLCD is discontinued at week +4, partici-
pants are weaned back onto food. This weaning takes 1
week; there is a gradual reducing of the lipotrim formula
which is replaced by low fat meals with a gradual
increase of carbohydrate until healthy proportions are
achieved. Gradual reintroduction of carbohydrate is
necessary in this way to avoid rapid replenishing and
storage of muscle glycogen, which could result in a
rapid increase of body water weight (up to 5 kg over the
week). At week +5 lifestyle goals are set and energy pre-
scription is given as described in treatment stage 1 of
IDAP. Behavioural support continues at reduced fre-
quency to week +12. The reason for this second stage of
treatment is to cultivate the development of long term
healthy habits as explained in the background section of
this paper.
Individually Tailored Dietary Planning (IDAP) This
behavioural support continues to week +12 with visits
becoming less frequent.
Control (Step by Step (SBS)) Participants in the control
arm, receive IDAP from week +8 to week +12. This
allows them time to become an established quitter
before they embark on weight control.
Smoking Cessation Interventions for all Patients
All participants have identical treatment to stop smok-
ing. This is the treatment which is available on the
NHS. It is withdrawal orientated such that behavioural
strategies and nicotine replacement are given to relieve
withdrawal symptoms. This has been shown to be an
effective model for stopping smoking [29]. Individuals
are seen over 7 consecutive weeks, weeks -3 and -2 pre-
pare them for quitting, they quit at week 0, weeks +1,
+2, +3 and +4 support them during the first 4 weeks
after quitting when withdrawal symptoms are at their
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vioural change techniques, pre-quit sessions prompt
intent formation (technique 4) by setting a quit date,
they prompt barrier identification (technique 5) and
relapse prevention (technique 23) when participants
identify times or places when it will be particular hard
f o rt h e mt or e s i s ts m o k i n g ,t h e yd i s c u s sas t r a t e g yt o
help them to deal with these circumstances; for exam-
ple, changing routine so the usual smoking cues are
removed. Quit week and the weeks that follow provide
instruction (technique 8) in the use of nicotine replace-
ment, review of and further planning of strategies (tech-
nique 11) to deal with withdrawal symptoms and
general encouragement (technique 6). Self-talk (techni-
que 22) is encouraged such that participants are asked
to see and describe themselves as a ‘non-smoker’ and to
frequently bring to mind the benefits of quitting that
they are looking forward to.
Nicotine replacement therapy (NRT) Nicorette 25 mg
transdermal 16 hour patches are provided for 8 weeks
followed by a 15 mg patch and a 10 mg patch each for
2 weeks. Patches are supplied free of charge by McNeil
Products Ltd. Other forms of NRT, such as gum or
nasal spray or a combination of NRT is not used to
avoid the possibility that the amount of NRT taken
would differ by arm. This could confound effects of
hunger or ketosis on urges to smoke that we are trying
to discover. We are using a nicotine patch as it delivers
a consistent amount of nicotine to avoid this confound-
ing. As no other NRT products can be used in combina-
tion to help with acute cravings we are using the 16
hour, 25 mg patch which has been shown to yield better
abstinence than other available patches [30].
Training and supervision
Treatment is provided by trained practice nurses. Train-
ing is given by NHS stop smoking services (2 days), a
research nurse and a general practitioner (GP) (1/2 day),
and a registered dietitian (1.5 days). Nurses are given
the clinical protocol to read before training sessions.
Training includes explanation of dietetic and beha-
vioural interventions and practicing the interventions on
each other. The clinical protocol is clarified where
needed and questions answered. The aim of the training
is to equip the nurses so that, once they have completed
it, they feel confident to deliver the interventions
according to the clinical protocol.
After the training, ‘hands on’ supervision is available
for the first few clinics. Immediate telephone access to
the dietitian and GP is available for all clinical queries
throughout the rest of the trial.
Medical history and any medication used or altered
during the trial is monitored. Any significant changes in
clinical condition of individual participants, as measured
on a weekly basis, is discussed with the supervising GP
and action taken, e.g. clinically significant fall in blood
pressure in participants on the VLCD taking anti-hyper-
tensives will require adjustment of anti-hypertensive
medication. The participant’s own GP is kept informed.
Fidelity checking and monitoring
Fidelity to the clinical protocol and record keeping is
assessed and monitored against the clinical protocol by
the principal investigator every few months; consulta-
tions are audiotaped for this purpose. Any deviations
are recorded, discussed and corrected either immedi-
ately or at following clinics. The trial is potentially sub-
ject to audit by the appropriate regulatory authorities
and therefore participants are asked to consent to allow
their records to be viewed.
Objectives
Primary objectives
To investigate the feasibility of running this three-armed
dietary intervention as part of the NHS stop smoking
services using primary care nurses,. This includes the
feasibility of measuring and monitoring of physiological
and biochemical risk factors for cardiovascular disease,
diabetes and chronic obstructive pulmonary disease
(COPD). It explores the acceptability of the interven-
tions to participants.
Secondary objectives
To investigate whether smoking cessation advice and a
nicotine patch in combination with: a very low calorie
diet (VLCD), or individually tailored dietary planning
(IDAP), or usual support affects urges to smoke,
through hunger or ketosis in overweight smokers trying
to quit.
Tertiary objectives
To investigate the extent to which changes in smoking
status, diet and activity achieved during the treatment
stages are maintained at the end of treatment and at 6
and 12 months in each of the intervention arms. To
investigate associations between hunger, abstinence,
early and late weight gain.
Outcome Measures
Acceptability
Participant acceptability is measured qualitatively by
semi-structured interviewing and quantitatively by
response and attrition rates as described below:
￿ Semi-structured telephone interviews are con-
ducted after the participant has completed or
dropped out of the trial. Participants who are happy
to do so will give their consent to this at the start of
the trial. To help them remember their thoughts and
feelings ‘of the moment’ they are given the questions
they will be asked at the start of the trial, with space
to jot down notes, during the trial. The number of
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theoretical saturation of responses has been reached.
We will purposively sample interviewees to encom-
pass the full range of attrition characteristics, for
example, those who completed the trial, and those
who dropped out of quitting, dieting or both in each
of the three trial arms. Interviews will be audio
recorded and transcribed verbatim. Participants will
be asked what they found helpful and unhelpful and
their reasons for dropping.
￿ Rates of response to participant invitation letters
and posters.
￿ Rates of recruitment at telephone screening, at first
consultation.
￿ Rates of drop out before randomisation.
￿ Rates of drop out after randomisation in each
treatment arm.
￿ Rates of attendance at each session.
￿ Rates of participant adherence to treatment.
￿ Quality of life measure, a scale on which the parti-
cipant can score general life satisfaction and well
being at baseline, weeks +4, and +12.
Feasibility
Feasibility of running the trial within the primary care
practice will be measured qualitatively as described
below:
￿ A focus group of participating clinicians to investi-
gate experiences of delivering intervention, e.g. how
easy was it to carry out the interventions, was train-
ing sufficient, was consultation time adequate, what
difficulties were encountered taking the trial
measurements.
￿ Principal investigator’s reflections on their experi-
ences of primary care involvement e.g. ease of GP
practice recruitment, willingness for PCTs to partici-
pant, obstacles encountered.
Cost
The financial cost of running the trial will be calculated.
Measurement of urges to smoke and hunger
Degree of smoking addiction is measured at baseline
using the Fagerstrom Score [31]. Urge to smoke is mea-
sured by the Mood & Physical Symptoms Combined
Scale (MPSS-C) [32]. Hunger and food craving is mea-
s u r e db yt h eH u n g e ra n df o o dC r a v i n g( H C S )s c o r e .
MPSS-C and HCS are recorded daily in a dairy over the
first four weeks of quitting and weekly thereafter. The
primary outcomes of interest will be over the first 24
hours and the first week of quitting; this is where the
largest effects are likely to be seen as withdrawal symp-
toms are at their peak during this time. Comparisons
between measures are made for all those who continued
in their quit attempt until they decided to abandon quit-
ting, and adjusted for those who lapsed, were point
prevalent abstinent at 24 hours, 7days or continuously
abstinent at 4 weeks. Although it is standard practice in
smoking trials to primarily analyse those who are absti-
nent, our interest is in the effects on cravings and we
cannot assume that those who did not achieve absti-
nence did not experience cravings as they tried to do so.
Piasecki showed that cravings were heightened in both
smokers who were attempting to quit and lapsed as well
as in smokers who succeeded in quitting. He found that
more cigarettes, smoked on more occasions did reduced
cravings (presumably as these have served to treat nico-
tine withdrawal acutely) but also that a few cigarettes
increased cravings (100 vs 56 cigarettes p < 0.001) [33].
P e r h a p st h i sr e f l e c t sag r e a t e rs t r u g g l et oc o p ew i t h
cravings before a cigarette was finally smoked out of
desperation.
Ketosis
The presence or absence of ketones will be measured
using ketostik test strips dipped into urine samples. This
will be done weekly during the first 6 weeks of dietary
intervention, this is to check those in the VLCD are in
ketosis throughout the five weeks and come out of keto-
sis during the re-feeding week. It is also measured dur-
ing this time in IDAP and control arms to verify the
a b s e n c eo fk e t o s i si nt h e s eg r o u p so ri d e n t i f ya n yp a r t i -
cipants which might be self-imposing excessive dietary
restriction, (unless undiagnosed diabetes presents itself).
Measurement of smoking status
Twenty-four hour point prevalence abstinence is mea-
sured by participants achieving 24 consecutive hours of
abstinence as verified by exhaled CO < 10 ppm. Seven
day point prevalence abstinence is defined as those not
smoking over the last 7 days as verified by exhaled CO
< 10 ppm. Participants achieving 1, 6 and 12 month
abstinence as defined using the Russell Standard which
states that no more than 5 cigarettes since have been
smoked since week +2, this is verified by CO < 10 ppm
at each consultation [34]. Participants who have not
achieved abstinence but are still attempting to quit are
termed ‘lapsed’.S m o k e r sw h oa b a n d o nt h e i rq u i t
attempt, such that it is no longer their intention to quit,
are considered ‘relapsed’.
Measurement of Disease Risk Factors
These are measured as described below. The schedule of
measurements is contained in table 2.
1. Weekly weight, waist to hip ratio, % body fat com-
position, blood pressure, and heart rate.
2. FEV1 and FVC post 200 mg salbutamol as is
recommended by the American Thoracic Society
2005 standards for measuring lung function [35] at
baseline, 3, 6 and 12 months.
3. Fasting blood glucose, Total cholesterol (TC), low
density lipoprotein (LDL) cholesterol, high density
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cerides, haemoglobin, white blood cell count, platelet
count, mean cell volume and c-reactive protein
(CRP).
Full details of how these measurements are taken are
contained within the trial clinical protocol as standard
operating procedures (SOPs) and work instructions
(WIs). The nurses are trained in these procedures so
that they are carried out consistently at each trial site.
The nurses are assessed in practice against these SOPs
and WIs, every couple of months, by the principal
investigator.
Measurement of diet and activity
Food choices, eating behaviour and activity are mea-
sured at baseline, end of treatment, 6 and 12 months
using the HCI. Agreement between this simple, quick
m e a s u r eo fd i e tq u a l i t yw i l lb ea s s e s s e db ys t a t i s t i c a l
analysis against a detailed seven day food intake diary
which is also completed at baseline. Participants are
encouraged to weigh their food when completing the
seven day food diary. Despite under-reporting in obese
individuals, a 7 day weighed intake diary has been
shown to be the most accurate measure of dietary intake
[36]. Diaries which report less than 1.2 × BMR energy
intake or are incomplete are discounted. If necessary the
Goldberg cut-off can be used to evaluate the mean
population bias in reported energy intake [37]. The
seven day diaries also measure physically activity levels
using the method which determined dietary references
values for energy in the UK.
Those on a VLCD who do not produce ketones or
achieve the expected 2 kg weekly weight loss will be
considered non adherent. We would expect any weight
gain in the IDAP group to be a result of poor adher-
ence, although weight maintenance is acceptable in this
group.
Confidence in trial arm
Due to the unblinded nature of the trial, participants are
asked prior to randomisation to rate their confidence of
each treatment arm being successful. This is measured
again at +4 and +12 weeks. We will be able to deter-
mine whether expectation of success in the treatment
they were allocated is associated with attrition rates.
Sample Size
Acceptability and feasibility is measured qualitatively
through interviews and by measurement of recruitment
and attendance rates. These outcomes are descriptive
and not analysed using statistical tests and so a power
calculation for them would be inappropriate.
The secondary aim is to identify whether dietary inter-
ventions affect cravings for cigarettes. In the trial by
Danielsson [25] the difference in cravings for cigarettes
at week 2 was mean 1.6 in the control and mean 1.1 in
the VLCD group with a standard deviation of 0.7. The
control in the Danielsson trial was a standard (not indi-
vidualised) 1600 kcal diet, a moderate energy restriction,
likely to lead to increased hunger. We are looking to
d e t e c tad i f f e r e n c eo ft h es a m em a g n i t u d eb e t w e e no u r
hungry (IDAP) and not hungry (control) or hunger sup-
pressed (VLCD) groups. Using Epicalc with 80% power
and a type 1 error rate of 5% we need 30 participants in
each group and 90 in total to detect a significant differ-
ence between them. For sufficient power to detect a dif-
ference in an abstinent subgroup, assuming a 60%
Table 2 Measurements to be taken at each point in trial
Treatment week -2 -1 0 1 2 3 4 5-7 8-10 12 26 52
Baseline Questionnaire (with Fagerstrom Score) 7 day food diary √
Weight √ √√√√√√ √√√ √ √
Waist/Hip ratio √ √√√√√√ √√√ √ √
BP/HR √ √√√√√√ √√√ √ √
Smoking Status √ √√√√√√ √√√ √ √
Urinary ketones √ √√√√√
Fasting Blood test √√ √ √
Lung function √√ √ √
Russell Standard √√ √ √
QOL measure √√ √
Confidence in trial arm √√ √
Percentage Body Fat composition √ √√√√√√ √√√ √ √
Daily Diaries √ √√√√√
Weekly Diaries √√ √ √ √ √
HCI √√ √ √
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recruit 42 in each group.
Such a trial would be large enough to differentiate
between dietary changes that reflect a poor to a healthy
diet using a dietary index, this is based on the figures by
Freisling et al in 2009 [38] who validated a food fre-
quency index using values of <32 and >39 for a poor
and very good diet respectively. With a standard devia-
tion of 5.7, 10 people would be needed in each arm to
detect a difference.
Running a larger trial to identify long term effects on
abstinence and weight is premature at this stage,
although we are carrying out all the measurements that
would be needed in such a trial to assess feasibility.
Randomisation
Randomisation is computer generated by an indepen-
dent statistician within the Primary Care Clinical
Research and Trials Unit (PCCRTU) using random per-
muted blocks of length 6, stratified by practice. The
numbers are entered into the trial database by an inde-
pendent computer programmer within the trials unit.
The database conceals randomisation until after partici-
pants have been screened and entered into the trial. At
week -3 the clinician clicks on the randomisation tab in
the database and this reveals the arm to which the parti-
cipant is allocated. The database is set up so that the
randomisation ‘tab’ will not work until all data from
week -2 has been completed. Therefore it is impossible
for anyone to see treatment allocation beforehand. This
greatly minimises any risk of the trial randomisation
being undermined.
Analysis and Statistical Methods
Semi-structured interview and focus group transcripts
will be coded according to content and common themes
regarding acceptability and feasibility will be identified.
Quantitative measures of acceptability will be pre-
sented as descriptive statistics.
The outcomes between the three arms of the study
will be compared using statistical tests on adequately
powered measures. Descriptive statistics (mean, SD and
95% CI) will be presented on underpowered measures.
Multilevel modelling based on the Piasecki model of
cigarette withdrawal [33] will be used to investigate the
effects of the dietary interventions on urges to smoke
during the first 4 weeks of quitting. We will investigate
whether these effects are mediated by hunger/food
craving score (HCS) and ketosis. We will adjust for
confounding variables e.g. active treatment for depres-
sion. Analysis will be carried out on all those who con-
tinued to try to quit regardless of lapses to smoking
and this will be adjusted for in the model as described
above.
Significance is set at the 5% level, exact p values
will be given and 95% confidence intervals where
appropriate.
Analysis of data from treatment stage 1 will be under-
taken once every participant has completed this stage.
Analysis from treatment stage 2 and follow-up at 6
months and one year will be undertaken once partici-
pants have gone through each of these phases.
Data Validation
Data cleaning will take place by a series of logical checks
on the electronic data. (For example, a person cannot be
recorded as prolonged abstinent smoker at 6 months if
they were not in such a state at 8 weeks). Discrepant
records are checked with the source documents and the
database amended if necessary.
Trial schedule
One Doctoral researcher is principal investigator and
supervising dietitian. Part-time support is provided by
practice research nurses and research administrators.
Recruiting will continue over a period of a year until
sufficient participants have been treated in each trial
arm. Follow up will take place as described and it is esti-
mated that the trial will be complete 2 years from the
start.
Definition of end of trial
End of trial is defined as the final 12 month follow-up
where the last measurement is taken from the last parti-
cipant and the last participant undergoing the trial is
debriefed.
Value of Results
The results from this study will provide new informa-
tion about dieting during smoking cessation. They will
inform the design of a multi-component intervention
that tackles both smoking cessation and its related
weight gain in a way which can be rolled out into the
NHS.
Assessment of safety
Potential participants’ safety is ensured by screening for
eligibility using a structured form completed by the trial
healthcare professionals. This will record evidence of elig-
ibility and that the person does not have any exclusion
criteria. In addition, the nurse will take a general medical
and drug history to assess for other complicating diseases.
Any queries remaining as a result of this process are
resolved by discussion between the trial nurse, chief
investigator and the relevant physicians providing routine
medical care, usually the participant’s GP. Such concerns
are unusual but not rare. Typically, they arise from a par-
ticipant’s hazy knowledge or understanding of their past
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or further medical testing is necessary to ensure safety.
VLCDs
Very low calorie diets are a recognised treatment for
obesity. They form part of the NICE (2006) guidelines
[14] for the management of adult obesity and are
advised for up to three months of continuous use in
p e o p l ew i t haB M I>3 0 .W ea r eu s i n gi tf o r5w e e k s
only in people with a BMI > 25. Weekly monitoring of
weight means that if BMI falls below a healthy level
treatment will be discontinued. VLCDs have been used
safely for many years including in people with a BMI
between 25 and 30 [16]. Since 1987 they have been sub-
ject to the regulations of the Committee on Medical
Aspects of Food [39]. This is an extensively researched
evidence based document detailing the formulation of
VLCDs to ensure safety. The product to be used in this
study complies with these standards. Thus, there is
every reason to expect that treatment in this trial is safe.
Participants are warned about the side-effects of
VLCDs and may contact the trial team to discuss any
concerns. To this end, all participants are given a card
the size of a credit card with the trial team’s contact
details on that will allow participants to receive advice
on the VLCD or to report perceived serious adverse
effects and receive advice as required. They are asked to
c a r r yt h i sc a r dw i t ht h e ma ta l lt i m e ss ot h a ti tc a nb e
used to notify medical personnel of a participant’s treat-
ment and trial involvement in case of emergency. Parti-
cipants will record the occurrence of side-effects of
VLCDs as specified by completing a checklist. The
checklist is given to the trial healthcare professional and
the healthcare professional will enquire about recorded
adverse events, so as to determine the severity of any
adverse event and ensure that appropriate advice is
given for its management (e.g. drinking appropriate
amounts of water to treat symptoms of mild dehydra-
tion.) Minor adverse reactions are monitored and mana-
ged in this way. For each known side effect listed in the
checklist, the trial healthcare professional will have a
definition of clinical severity. Any side effect that is clas-
sified as moderate or severe is reported to and discussed
with the principal investigator. A decision on stopping
therapy will then be made with the participant, attend-
ing clinician, principal investigator and other relevant
parties as appropriate.
Dietary and Lifestyle Advice
Healthy dietary and lifestyle advice is individually tai-
lored to create a mild energy deficit and gentle increase
in activity. This advice is given by appropriately trained
healthcare professionals. It is usual practice and consid-
ered very safe. In the unlikely event of side effects parti-
cipants may contact the trial team to discuss any
concerns. To this end, all participants are given a credit
card-sized card with the trial team’s contact details on
that will allow participants to report perceived serious
adverse effects and receive advice as required.
NRT Patches
NRT has been investigated in several hundred previous
clinical trials and is widely prescribed worldwide and
subject to safety monitoring, and is replacing a product,
nicotine, which the participants are already consuming
and will have consumed for many years in cigarettes.
Thus, there is every reason to expect that treatment in
this trial is safe. Participants are warned about the side-
effects of NRT and advised not to stop taking the medi-
cation without consulting with the trial team or an NHS
professional if the trial team are unavailable. Participants
will record the occurrence of side-effects of medication
as specified on the summary of product characteristics
(SPC) for all relevant NRT preparations, by completing
a checklist. The checklist is given to the trial healthcare
professional and the healthcare professional will enquire
about recorded adverse events, so as to determine the
severity of any adverse event and ensure that appropri-
ate advice is given for its management (such as rotating
the patch site or use of emollients for skin reactions).
Minor adverse reactions are monitored and managed in
this way. For each known side effect listed in the SPC,
the trial healthcare professional will have a definition of
clinical severity. For example, a mild skin site reaction
to the patch is defined as burning sensation that does
not interfere with normal activities, redness or swelling
at the site of application, or mild blistering. Any reac-
tion beyond that is classified as potentially moderate or
severe and is reported to and discussed with the princi-
pal investigator. A decision on stopping therapy will
then be made with the participant, attending clinician,
principal investigator, and other relevant parties as
appropriate. Nicotine has a short half life (2 hours),
meaning that the blood concentration will not build up
during the course of treatment so that new side-effects
are not expected after the first few weeks. In addition,
reactions to it relate to local use, such as skin discom-
fort from patches and people become accustomed to the
side-effects after a short time of using the preparation.
The advice given will depend upon the severity of the
reported reaction and those with moderate reactions are
invited to an ad hoc consultation.
The SPCs for the relevant NRT products contain no
warnings about serious adverse reactions except rare
allergic reactions, such as angioedema, and cardiac
arrhythmias, occurring in less than 1/1000 users. Thus
we expect no or very few SUSARs (suspected unex-
pected serious adverse reaction) in this trial. The long
history of use in and outside of trials for NRT means
that SUSARs are unlikely. On the reverse of the trial
card given the contact number for advice on side-effect
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ious adverse events. Through direct contact from the
participant or contact from their attending physician, we
expect to become aware of serious adverse events. If any
member of the trial team becomes aware, they will
inform the principal investigator within 24 hours. The
principal investigator will then assess the seriousness,
causality, expectedness and severity of the adverse
effects. An immediate decision is made on the interim
use of medication for that participant. If an event is
judged severe, it is reported to the trial sponsor, who
will report the event to the REC. Definitions of adverse
events are contained in additional file 3.
Salbutamol
Salbutamol has been thoroughly investigated in clinical
trials and is widely prescribed worldwide and subject to
safety monitoring. Thus, there is every reason to expect
that its use in this trial is safe. Common side effects to
salbutamol are mild (e.g. headache, tremor) and rare
with small doses; severe reaction is very rare. Any reac-
tion tends to be immediate. Participants are warned
about the side-effects of salbutamol and asked to give
verbal consent to taking it. They will take a small dose
(200 mcg) in the company of healthcare professionals
and given a contact number should they experience any
adverse events in the hours that follow. This is adminis-
tered 4 times during the year, at baseline, 12 weeks,
6months and 1 year. For each known side effect listed
in the SPC, the trial healthcare professional will have a
definition of clinical severity. Any reaction beyond that
is classified as potentially moderate or severe and is
reported to and discussed with the principal investiga-
tor. If it is felt that a person has suffered side-effects
which are related to the salbutamol then they will not
have the salbutamol administered next time.
The long history of use in and outside of trials for
salbutamol means that SUSARs are unlikely. On the
reverse of the trial card given the contact number for
advice on side-effect management, there are instruc-
tions for the reporting of serious adverse events.
Through direct contact from the participant or contact
from their attending physician, we expect to become
aware of serious adverse events. If any member of the
trial team becomes aware, they will inform the princi-
pal investigator within 24 hours. The principal investi-
gator will then assess the seriousness, causality,
expectedness and severity of the adverse effects. If an
event is judged severe, it is reported to the trial spon-
sor, who will report the event to the Research Ethics
Committee (REC). Definitions of adverse events are
contained in additional file 3.
Participants are asked weekly to report intercurrent
illnesses and the response recorded. If any of these
intercurrent illnesses contra-indicates Salbutamol, NRT,
VLCD or Healthy Dietary Advice, this is immediately
reported to the principal investigator and a decision
made about continued use.
Ethics and Research Governance
The trial is conducted in compliance with the principles
of the Declaration of Helsinki (1996), the principles of
the International Conference on Harmonisation (ICH)-
Good Clinical Practice (GCP) and run in accord with
EU Clinical Trials Directive and all of the applicable
regulatory requirements. The study protocol and other
documentation have been approved by South Birming-
ham Research Ethics Committee, Birmingham and Black
Country Comprehensive Local Research Network and
West Midlands South Comprehensive Local Research
Network. Any subsequent protocol amendments will be
submitted to the REC for approval and the other bodies
if necessary. We will comply with ICH-GCP Guidelines
over the reporting of adverse events (AEs), serious
adverse events (SAEs) and suspected unexpected serious
adverse reaction SUSARs. In addition we will provide
the REC with progress reports as well as a copy of the
final study report.
Data management, protection and confidentiality
The trial is being run as part of the portfolio of trials
in the Primary Care Clinical Research and Trials Unit
(PCCRTU), NIHR accredited trials unit number 33, in
Primary Care Clinical Sciences at the University of Bir-
mingham. The data management is run in accord with
the standard operating procedures (SOPs), which are
fully compliant with the Data Protection Act and ICH
GCP. The trial registered with the Data Protection Act
website at the University of Birmingham. Patient iden-
tifiable data is shared only within the clinical team on
a need-to-know basis to provide clinical care and
ensure good and appropriate follow up. Patient identi-
fiable data will also be shared with the GP and
approved auditors from the REC or NHS Research &
Development (R&D) will also be able to see patient
identifiable information. Otherwise, confidentiality is
maintained and no one outside the trial team will have
access to either the case report forms (CRFs) or the
database. The source documents for the trial are CRFs
which are stored in a locked cabinet at the participat-
ing practice. The trial database is securely held and
maintained by the PCCRTU. On completion of the
trial and data checking, the CRFs are transferred to
Modern Records, a secure archiving facility at the Uni-
v e r s i t yo fB i r m i n g h a m ,w h e r et h e ya r eh e l df o r1 5
years and then destroyed. The database is anonymised
and a secure CD containing the link between ID num-
ber and patient identifiable information is stored in
modern records.
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The study is funded by UK Centre for Tobacco Control
Studies (UKCTCS) and service support costs from the
Comprehensive Clinical Research Network.
Publication
The trial results will be written up for submission to a
peer reviewed journal and the trial is registered with
ISRCTN. No data relating to individuals will be identi-
fied in these publications.
Additional material
Additional file 1: Substantial Amendment. Details of an approved
substantial amendment to this trial protocol regarding improving
recruitment rates.
Additional file 2: Safe Use of Low Dose Diuretics with a VLCD.
Clinical protocol, for use in this trial only, for the safe use of a VLCD with
low dose diuretics used to treat hypertension.
Additional file 3: Adverse Event Reporting. Definitions of adverse
events and responsibilities for reporting them.
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